Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Volume 33(4); 2006 > Article
Phase III Clinical Trial of Revaprazan (Revanex) for Gastritis
[Epub ahead of print]
DOI: https://doi.org/
Published online: October 30, 2006
Department of Gastroenterology, The Catholic University of Korea College of Medicine, Seoul, *Kyungpook National University College of Medicine, Daegu, Kyunghee University College of Medicine, Seoul, Dong-A University College of Medicine, Busan, Pusan National University College of Medicine, Busan, §Ajou University College of Medicine, Suwon, Yonsei University College of Medicine, Seoul, **Yonsei University Wonju College of Medicine, Wonju, ††Yeungnam University College of Medicine, Daegu, ‡‡Wonkwang University College of Medicine, Iksan, ∥∥Inje University College of Medicine, Busan, §§Chonnam National University College of Medicine, Gwangju, ¶¶Hallym University College of Medicine, Chuncheon, ***Hanyang University College of Medicine, Seoul, †††Yuhan Corporation, Seoul, Korea
  • 4,587 Views
  • 100 Download
  • 0 Crossref
  • 0 Scopus
prev next

Background
/Aims: We performed a randomized, double-blind, phase III, multicenter trial to assess the comparative efficacy and safety of revaprazan, which is a novel acid pump antagonist in comparison with ranitidine for treating patients suffering with acute gastritis and acute aggravation of chronic gastritis. Methods: Five hundred and twelve subjects were randomized to 2 weeks of treatment with either revaprazan 200 mg q.d. or ranitidine 150 mg b.i.d. The primary efficacy parameter was the estimated improvement rate according to endoscopy, and the secondary efficacy parameter was the improvement rate for the subjects' symptoms. Results: The estimated improvement rates at 2 weeks (intention-to-treat analysis) were 79.9% with revaprazan and 60.5% with ranitidine; a significant difference was found between the two groups (p<0.0001). On the per-protocol analysis, the estimated improvement rates for revaprazan and ranitidine were 79.4% and 60.2%, respectively. There was a significant difference in the estimated improvement rates between the two groups (p<0.0001). On both analyses, there were no significant differences between the two groups for the improvement rates of the subjects' symptoms. Both drugs were well tolerated. Conclusions: The efficacy of revaprazan was higher than that of ranitidine for the estimated improvement rate according to endoscopy and also for the symptomatological improvement rate, and revaprazan was well tolerated by the subjects suffering with gastritis. (Korean J Gastrointest Endosc 2006;33:212⁣219)


Clin Endosc : Clinical Endoscopy Twitter Facebook
Close layer
TOP